Deutsch Luisa
Sciopsis Inc. Evidence Based NutraMedicine, 18 Corso Court, Richmond Hill, Ontario L4S 1H4, CANADA.
J Am Coll Nutr. 2007 Feb;26(1):39-48. doi: 10.1080/07315724.2007.10719584.
a) To evaluate the effect of Neptune Krill Oil (NKO) on C-reactive protein (CRP) on patients with chronic inflammation and b) to evaluate the effectiveness of NKO on arthritic symptoms.
Randomized, double blind, placebo controlled study. Ninety patients were recruited with confirmed diagnosis of cardiovascular disease and/or rheumatoid arthritis and/or osteoarthritis and with increased levels of CRP (>1.0 mg/dl) upon three consecutive weekly blood analysis. Group A received NKO (300 mg daily) and Group B received a placebo. CRP and Western Ontario and McMaster Universities (WOMAC) osteoarthritis score were measured at baseline and days 7, 14 and 30.
After 7 days of treatment NKO reduced CRP by 19.3% compared to an increase by 15.7% observed in the placebo group (p = 0.049). After 14 and 30 days of treatment NKO further decreased CRP by 29.7% and 30.9% respectively (p < 0.001). The CRP levels of the placebo group increased to 32.1% after 14 days and then decreased to 25.1% at day 30. The between group difference was statistically significant; p = 0.004 at day 14 and p = 0.008 at day 30. NKO showed a significant reduction in all three WOMAC scores. After 7 days of treatment, NKO reduced pain scores by 28.9% (p = 0.050), reduced stiffness by 20.3% (p = 0.001) and reduced functional impairment by 22.8% (p = 0.008).
The results of the present study clearly indicate that NKO at a daily dose of 300 mg significantly inhibits inflammation and reduces arthritic symptoms within a short treatment period of 7 and 14 days.
a)评估海王星磷虾油(NKO)对慢性炎症患者C反应蛋白(CRP)的影响;b)评估NKO对关节炎症状的疗效。
随机、双盲、安慰剂对照研究。招募了90名确诊患有心血管疾病和/或类风湿性关节炎和/或骨关节炎且连续三周每周血液分析时CRP水平升高(>1.0mg/dl)的患者。A组接受NKO(每日300mg),B组接受安慰剂。在基线以及第7、14和30天测量CRP和西安大略和麦克马斯特大学(WOMAC)骨关节炎评分。
治疗7天后,NKO使CRP降低了19.3%,而安慰剂组则升高了15.7%(p=0.049)。治疗14天和30天后,NKO分别使CRP进一步降低了29.7%和30.9%(p<0.001)。安慰剂组的CRP水平在14天后升高至32.1%,然后在第30天降至25.1%。组间差异具有统计学意义;第14天p=0.004,第30天p=0.008。NKO在所有三项WOMAC评分中均显示出显著降低。治疗7天后,NKO使疼痛评分降低了28.9%(p=0.050),僵硬程度降低了20.3%(p=0.001),功能障碍降低了22.8%(p=0.008)。
本研究结果清楚地表明,每日剂量300mg的NKO在7至14天的短治疗期内可显著抑制炎症并减轻关节炎症状。